Sara Tinsley, PhD, APRN, AOCN, on B-Cell Lymphoma: Phase Ib/II Data on ViPOR for Relapsed or Refractory Disease

Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses early insights for advanced practitioners on the safety, efficacy, and toxicities of the drug regimen known as ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) for patients with relapsed or refractory B-cell lymphoma (Abstract 598).